Ua hoʻolaha ʻo Jubilant Therapeutics Inc. i kēia lā i ka hoʻohana ʻana o ka mea maʻi mua i kahi hoʻokolohua lapaʻau Phase I/II o JBI-802 i nā maʻi me nā maʻi maʻi paʻa kiʻekiʻe. ʻO JBI-802 kahi papa mua, liʻiliʻi-mole, i hāʻawi waha ʻia i ʻelua inhibitor o LSD1 a me HDAC6 i hōʻike i ka hana anti-tumor synergistic i nā ʻano holoholona.
ʻO ka hoʻāʻo ʻana o ka Phase I/II he hōʻailona wehe, ʻelua ʻāpana escalation dose a me ka hoʻonui ʻana i hoʻolālā ʻia e wehewehe i ka palekana a me ka hoʻomanawanui, e ʻimi i nā biomarkers wānana a loiloi i ka hana mua o JBI-802 ma mua o 100 mau mea noiʻi me nā maʻi koko paʻa. Hiki ke loaʻa ka ʻike hou aku e pili ana i ka hoʻokolohua lapaʻau ma NCT05268666.
Ua haʻi ʻo Hari S Bhartia, Luna Hoʻomalu, Jubilant Therapeutics Inc. ma ka hoʻolaha, "Ua hele lōʻihi mai mākou mai ka ʻike ʻana i ka lāʻau lapaʻau a hiki i ka dosing mua i loko o ke kanaka. Manaʻo mākou i ka hoʻololi ʻana i ke ola o nā maʻi. ʻO kā mākou ʻike i ka hoʻolālā lāʻau lapaʻau i hoʻokumu ʻia a me ka kemika lāʻau lapaʻau e hiki ai iā mākou ke hana i nā therapeutics precision ʻokoʻa me nā waiwai hou.
Ua ʻōlelo ʻo Syed Kazmi, Luna Nui, Jubilant Therapeutics Inc., "JBI-802, hoʻololi maikaʻi i ʻelua mau pahuhopu oncology i hoʻopaʻa ʻia me ka like like a me nā kinetics hōʻike wikiwiki, e alakaʻi ana i ka hana anti-tumor synergistic me kahi hōʻemi o ka thrombocytopenia. ʻO kēia kā mākou moho huahana i kūkulu ʻia mua e komo i ka hoʻomohala lapaʻau. ʻO nā papahana holomua ʻē aʻe e pili ana i kahi mea paʻa o ka lolo oral penetrant o PRMT5, JBI 778, a me ka lolo oral penetrant PDL1 inhibitor, JBI 2174, no nā maʻi maʻi neurological ma waena o kekahi.
He aha e lawe ʻia mai kēia ʻatikala:
- The Phase I/II trial is an open label, two-part dose escalation and expansion study designed to define the safety and tolerability, explore predictive biomarkers and assess preliminary activity of JBI-802 in more than 100 study participants with advanced solid tumors.
- today announced the dosing of the first patient in a Phase I/II clinical trial of JBI-802 in patients with advanced solid tumors.
- JBI-802 is a first-in-class, small-molecule, orally administered dual inhibitor of LSD1 and HDAC6 that has demonstrated synergistic anti-tumor activity in animal models.
